These novel and experimental therapies have the potential of drastically altering our understanding of and approach to airway disease. We indeed live in interesting times.
GaensslenM.Über inhalation von Insulin. Wein Klin. Wochenschr.1925;2:71–72.
2.
DesaiMA, MutluM, VadgamaP.A study of macromolecular diffusion through native porcine mucus. Experientia1992;48(1):22–26.
3.
BhatPG, FlanaganDR, DonovanMD. Drug diffusion through cystic fibrotic mucus: steady-state permeation, rheologic properties, and glycoprotein morphology. J Pharm Sci1996;85(6):624–630.
4.
SchürchS, GehrP, Im HofV, GeiserM, GreenF.Surfactant displaces particles toward the epithelium in airways and alveoli. Respir Physiol1990;80(1):17–32.
5.
KharaschVS, SweeneyTD, FredbergJ, LehrJ, DamokoshAI, AveryME, BrainJD. Pulmonary surfactant as a vehicle for intratracheal delivery of technetium sulfur colloid and pentamidine in hamster lungs. Am Rev Respir Dis1991;144(4):909–913.
6.
AdlerKB, FischerBM, WrightDT, CohnLA, BeckerS.Interactions between respiratory epithelial cells and cytokines: relationships to lung inflammation (review). Ann NY Acad Sci1994;725:128–145.
7.
TamaokiJ, ChiyotaniA, KobayashiK, SakaiN, KanemuraT, TakizawaT.Effect of indomethacin on bronchorrhea in patients with chronic bronchitis, diffuse panbronchiolitis, or bronchiectasis. Am Rev Respir Dis1992;145(3):548–552.
8.
VogelmeierC, GillissenA, BuhlR.Use of secretory leukoprotease inhibitor to augment lung antineutrophil elastase activity (review). Chest1996;110 (6 Suppl):261S–266S.
9.
McElvaneyNG, NakamuraH, BirrerP, HebertCA, WongWL, AlphonsoM, . Modulation of airway inflammation in cystic fibrosis: in vivo suppression of interleukin-8 levels on the respiratory epithelial surface by aerosolization of recombinant secretory leukoprotease inhibitor. J Clin Invest1992;90(4):1296–1301.
SmithRM, SpraggRG. Production and administration to dogs of aerosois of alpha-1-proteinase inhibitor. Am J Med1988;84(6A):48–51.
16.
LackG, RenzH, SalogaJ, BradleyKL, LoaderJ, LeungDY, . Nebulized but not parenteral IFN-gamma decreases IgE production and normalizes airways function in a murine model of allergen sensitization. J Immunol1994;152(5):2546–2554.
17.
MartinRJ, BoguniewiczM, HensonJE, OelnikerAC, WilliamsM, GiornoRC, LeungDY. The effects of inhaled interferon gamma in normal human airways. Am Rev Respir Dis1993;148(6 Pt 1):1677–1682.
18.
GiosueS, CasariniM, AlemannoL, GalluccioG, MattiaP, PedicelliG, . Effects of aerosolized interferon-alpha in patients with pulmonary tuberculosis. Am J Respir Crit Care Med1998;158(4):1156–1162.
19.
BuhlR, MeyerA, VogelmeierC.Oxidant-protease interaction in the lung: prospects for antioxidant therapy (review). Chest1996;110 (6 Suppl):267S–272S.
20.
GillissenA, RoumJH, HoytRF, CrystalRG. Aerosolization of superoxide dismutase: augmentation of respiratory epithelial lining fluid antioxidant screen by aerosolization of recombinant human Cu ++/Zn ++ superoxide dismutase. Chest1993;104(3):811–815.
21.
HybertsonBM, KitlowskiRP, JepsonEK, RepineJE. Supercritical fluid-aerosolized vitamin E pretreatment decreases leak in isolated oxidant-perfused rat lungs. J Appl Physiol1998;84(1):263–268.
22.
MorgenrothK, BolzJ.Morphological features of the interaction between mucus and surfactant on the bronchial mucosa. Respiration1985;47(3):225–231.
23.
RubinBK, TomkiewiczRP, KingM.Mucoactive agents: old and new. In: WilmottRW, editor. The pediatric lung. Basel, Switzerland: Birkhäuser Publishing; 1997:155–179.
24.
KingM, RubinBK. Mucus rheology: relationship with transport. In: TakishimaT, editor. Airway secretion: physiological bases for the control of mucus hypersecretion. New York: Marcel Dekker; 1994:283–314.
PuchelleE, ZahmJM, GirardF, BertrandA, PoluJM, AugF, SadoulP.Mucociliary transport in vivo and in vitro: relations to sputum properties in chronic bronchitis. Eur J Respir Dis1980;61(5):254–264.
27.
RubinBK, MacLeodPM, SturgessJ, KingM.Recurrent respiratory infections in a child with fucosidosis: is the mucus too thin for effective transport?Pediatr Pulmonol1991;10(4):304–309.
28.
DueholmM, NielsenC, ThorshaugeH, EvaldT, HansenNC, MadsenHD, MaltbaekN.N-acetylcysteine by metered dose inhaler in the treatment of chronic bronchitis: a multi-centre study. Respir Med1992;86(2):89–92.
29.
HansenNCG, SkriverA, Brorsen-RiisL, BalslovS, EvaldT, MaltbaekN, . Orally administered N-acetylcysteine may improve general well-being in patients with mild chronic bronchitis. Respir Med1994;88(7):531–535.
30.
VentrescaGP, Cicchetti, FerrariV.Acetylcysteine. In: BragaPC, AllegraL, editors. Drugs in bronchial mucology. New York: Raven Press; 1989:77–102.
31.
TomkiewiczRP, AppEM, De SanctisGT, CoffinerM, MaesP, RubinBK, KingM.A comparison of a new mucolytic N-acetylcysteine L-lysinate with N-acetylcysteine: airway epithelial function and mucus changes in dog. Pulm Pharmacol1995;8(6):259–265.
32.
FengW, GarrettH, SpeertDP, KingM.Improved clearability of cystic fibrosis sputum with dextran treatment in vitro. Am J Respir Crit Care Med1998;157(3 Pt 1):710–714.
33.
TomkiewiczRP, KishiokaC, FreemanJ, RubinBK. DNA and actin filament ultrastructure in cystic fibrosis sputum. In: BaumG.Cilia, mucus, and mucociliary interactions. New York: Marcel Dekker; 1998:333–341.
34.
ShakS.Aerosolized recombinant human DNase I for the treatment of cystic fibrosis (review). Chest1995;107(2 Suppl):65S–70S.
35.
FuchsHJ, BorowitzDS, ChristiansenDH, MorrisEM, NashML, RamseyBW, . Effect of aerosolized recombinant human DNase on exacerbations of respiratory symptoms and on pulmonary function in patients with cystic fibrosis. The Pulmozyme Study Group. N Engl J Med1994;331(10):637–642.
36.
O'DonnellAE, BarkerAF, IlowiteJS, FickRB. Treatment of idiopathic bronchiectasis with aerosolized recombinant human DNase I. rhDNase Study Group. Chest1998;113(5):1329–1334.
37.
FielSB, FuchsHJ, JohnsonC, GondaI, ClarkAR. Comparison of three jet nebulizer aerosol delivery systems used to administer recombinant human DNase I to patients with cystic fibrosis. The Pulmozyme rhDNase Study Group. Chest1995;108(1):153–156.
38.
ShahPL, ScottSF, GeddesDM, HodsonME. Two years experience with recombinant human DNase I in the treatment of pulmonary disease in cystic fibrosis. Respir Med1995;89(7):499–502.
39.
GellerDE, EigenH, FielSB, ClarkA, LamarreAP, JohnsonCA, KonstanMW. Effect of smaller droplet size of dornase alfa on lung function in mild cystic fibrosis. Dornase Alfa Nebulizer Group. Pediatr Pulmonol1998;25(2):83–87.
40.
CipollaDC, ClarkAR, ChanH-K, GonjaI, ShireSJ. Assessment of aerosol delivery systems for recombinant human deoxyribonuclease. STP Pharma Sci1994;4:50–62.
41.
VasconcellosCA, AllenPG, WohlME, DrazenJM, JanmeyPA, StosselTP. Reduction in viscosity of cystic fibrosis sputum in vitro by gelsolin. Science1994;263(5149):969–971.
42.
RubinBK, KaterAP, DianT, RamirezOE, TomkiewiczRP, GoldsteinAL. Effects of thymosin beta 4 on cystic fibrosis sputum. Pediatr Pulmonol Suppl1995;12:234.
43.
RubinBK. Pharmacologic management of mucus retention based on a taxonomy of mucoactive medications. In: BaumG.Cilia, mucus, and mucociliary interactions. New York: Marcel Dekker; 1988:383–389.
44.
RubinBK, KishiokaC, van der SchansCP, DowellA, FielS.Mucus and mucoactive therapy in chronic bronchitis. Clin Pulm Med1998;5:1–14.
45.
KnowlesMR, HohnekerKW, ZhouZ, OlsenJC, NoahTL, HuPC, . A controlled study of adenoviral-vector-mediated gene transfer in the nasal epithelium of patients with cystic fibrosis. N Engl J Med1995;333(13):823–831.
46.
McDonaldRJ, LukasonMJ, RaabeOG, CanfieldDR, BurrEA, KaplanJM, . Safety of airway gene transfer with Ad2/CFTR2: aerosol administration in the nonhuman primate. Hum Gene Ther1997;8(4):411–422.
47.
SeneC, BoutA, ImlerJL, SchultzH, WillemotJM, HennebelV, . Aerosol-mediated delivery of recombinant adenovirus to the airways of nonhuman primates. Hum Gene Ther1995;6(12):1587–1593.
48.
BellonG, Michel-CalemardL, ThouvenotD, JagneauxV, PoitevinF, MalcusC, . Aerosol administration of a recombinant adenovirus expressing CFTR to cystic fibrosis patients: a phase I clinical trial. Hum Gene Ther1997;8(1):15–25.
49.
FlotteTR, CarterBJ. In vivo gene therapy with adeno-associated virus vectors for cystic fibrosis (review). Adv Pharmacol1997;40:85–101.
50.
NaldiniL, BlomerU, GallayP, OryD, MulliganR, GageFH, . In vivo gene delivery and stable transduction of nondividing cells by a lentiviral vector. Science1996;272(5259):263–267.
51.
GillDR, SouthernKW, MoffordKA, SeddonT, HuangL, SorgiF, . A placebo-controlled study of liposome-mediated gene transfer to the nasal epithelium of patients with cystic fibrosis. Gene Ther1997;4(3):199–209.
52.
EastmanSJ, LukasonMJ, TousignantJD, MurrayH, LaneMD, St GeorgeJA, . A concentrated and stable aerosol formulation of cationic lipid: DNA complexes giving high-level gene expression in mouse lung. Hum Gene Ther1997;8(6):765–773.
53.
PillaiR, PetrakK, BlezingerP, DeshpandeD, FlorackV, FreimarkB, . Ultrasonic nebulization of cationic lipid-based gene delivery systems for airway administration. Pharm Res1998;15(11):1743–1747.
54.
SternM, CaplenNJ, BrowningJE, GriesenbachU, SorgiF, HuangL, . The effect of mucolytic agents on gene transfer across a CF sputum barrier in vitro. Gene Ther1998;5(1):91–98.
55.
GendlerSJ, SpicerAP. Epithelial mucin genes (review). Annu Rev Physiol1995;57:607–634.
56.
RubinBK. Emerging therapies for cystic fibrosis lung disease (review). Chest1999;115(4):1120–1126.
